The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

ClinicalTrials.gov ID: NCT05203172

Public ClinicalTrials.gov record NCT05203172. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 12, 2026, 10:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

ENCORAFENIB/BINIMETINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM ENCORAFENIB/BINIMETINIB CLINICAL STUDIES

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this clinical trial (called the FLOTILLA study) is to give continued access to the study medicines, as well as safety follow-up, for participants in prior clinical trials of encorafenib and/or binimetinib. All participants who took part in earlier encorafenib and/or binimetinib studies may participate the FLOTILLA study if they are still benefiting from the use of the study medicines. This will be determined by the study doctor. People may not participate in the FLOTILLA study if they have not enrolled in a prior study of encorafenib or binimetinib. Participants that had enrolled but had stopped receiving the study treatment in a prior study cannot enrolled in this study. Participants in the FLOTILLA study will receive encorafenib and/or binimetinib at the same dose and frequency as in their prior study, for up to about 5 years.

Study identification

NCT ID: NCT05203172
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 4
Lead sponsor: Pfizer; Industry
Enrollment: 46 participants

Conditions and interventions

Conditions

Solid Tumors

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 4, 2022
Primary completion: Jul 30, 2029
Completion: Jul 30, 2029
Last update posted: Apr 6, 2026

2022 – 2029

United States locations

U.S. sites: 18
U.S. states: 8
U.S. cities: 8

Facility	City	State	ZIP	Site status
St. Joseph's Hospital and Medical Center	Phoenix	Arizona	85004	Recruiting
St. Joseph's Hospital and Medical Center	Phoenix	Arizona	85013	Recruiting
Emory University Hospital Midtown	Atlanta	Georgia	30308	Recruiting
Emory University Hospital	Atlanta	Georgia	30322	Recruiting
Investigational Drug Service Emory University Clinic	Atlanta	Georgia	30322	Recruiting
Winship Cancer Institute of Emory University	Atlanta	Georgia	30322	Recruiting
Massachusetts General Hospital	Boston	Massachusetts	02114	Recruiting
HealthPartners Cancer Research Center	Saint Paul	Minnesota	55101	Recruiting
Regions Hospital Pharmacy	Saint Paul	Minnesota	55101	Recruiting
Siteman Cancer Center	St Louis	Missouri	63108	Recruiting
Barnes-Jewish Hospital	St Louis	Missouri	63110	Recruiting
Washington University School of Medicine	St Louis	Missouri	63110	Recruiting
Washington University	St Louis	Missouri	63110	Recruiting
MSK Basking Ridge	Basking Ridge	New Jersey	07920	Active, not recruiting
Rockefeller Outpatient Pavilion (53rd Street)	New York	New York	10022	Active, not recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Active, not recruiting
Duke Cancer Center	Durham	North Carolina	27710	Recruiting
Investigational Chemotherapy Service	Durham	North Carolina	27710	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 49 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05203172, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 6, 2026 · Synced Sep 12, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05203172 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →